Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone

Gulnur Sh. Burbaeva, Irina S. Boksha, Marina S. Turishcheva, Olga K. Savushkina, Alan G. Beniashvili, Georgiy E. Rupchev, Margarita A. Morozova

.

DOI: 10.4236/health.2011.31003                

Abstract

Objectives: Testing a hypothesis, that platelet cytochrome c-oxidase (COX) activities in patients with paranoid schizophrenia, acute episode, may be linked to dynamics of their clinical patterns and quality of cognitive functioning under antipsychotic treatment. Methods: Psychopatho-logical (PANSS, NSA-16) and cognitive assess-ments; platelet COX enzymatic activity determination, post-hoc nonparametric statistical analysis. Results: Psychopathological and cognitive assessments were done and blood was sampled in patients before (at baseline) and after treatment with risperidone. Following regu- larities were found after the treatment of patients: Significant elevation of COX, wherein the higher was COX at baseline, the more prominent was decrease in PANSSneg and NSA rates; significant negative correlation between COX and executive time in cognitive tests. When the patient group was divided by median of COX at baseline into two subgroups (greater or equal median, and 20% was assigned to the first subgroup; significantly larger amount of patients with PANSSneg by <20% was assigned to the second group. Conclusions: Therapy with risperidone seems to be more effective for patients with higher COX activity at baseline, but this fact requires further study.

Keywords

Schizophrenia; Risperidone; Biochemical Markers; Acute Phase Treatment; Atypical Antipsychotics

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Mohanakrishnan, P., Fowler, A.H., Vonsattel, J.P., Husain, M.M., Jolles, P.R., Liem, P. and Komoroski, R.A. (1995) An in vitro ?H nuclear magnetic resonance study of the tempoparietal cortex of Alzheimer brains. Experimental Brain Research, 102, 503-510. doi:10.1007/BF00230654
[2]	Kennedy, A.M., Frackowiak, R.S., Newman, S.K., Bloomfield, P.M., Seaward, J., Roques, P., Lewington, G., Cunningham, V.J. and Rossor, M.N. (1995) Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer’s disease. Neuroscience Letters, 186, 17-20. doi:10.1016/0304-3940(95)11270-7
[3]	Volz, H.R., Riehemann, S., Maurer, I., Smesny, S., Sommer, M., Rzanny, R., Holstein, W., Czekalla, J. and Sauer, H. (2000) Reduced phosphodiesters and high- energy phosphates in the frontal lobe of schizophrenic patients: A 31P chemical shift spectroscopic-imaging study. Biological Psychiatry, 47, 954-961. doi:10.1016/S0006-3223(00)00235-3
[4]	Maurer, I., Zierz, S. and Moller, H.-J. (2001) Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophrenia Research, 48, 125-136. doi:10.1016/S0920-9964(00)00075-X
[5]	Fukuzako, H. (2001) Neurochemical investigation of the schizophrenic brain by in vivo phosphorus magnetic resonance spectroscopy. The World Journal of Biological Psychiatry, 2, 70-82. doi:10.3109/15622970109027496
[6]	Jou, S.-H., Chiu, N.-Y. and Liu, C.-S. (2009) Mitochondrial dysfunction and psychiatric disorders. Chang Gung Medical Journal, 32, 370-379.
[7]	Buchsbaum, M.S. and Hazlett, E.A. (1998) Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophrenia Bulletin, 24, 343-364.
[8]	Cavelier, L., Jazin, E.E., Eriksson, I., Prince, J., Bave, U., Oreland, L. and Gyllensten, U. (1995) Decreased cytochrome c-oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics, 29, 217-224. doi:10.1006/geno.1995.1234
[9]	Shao, L., Martin, M.V., Watson, S.J., Schatzberg, A., Akil, H., Myers, R.M., Jones, E.G., Bunney, W.E. and Vawter, M.P. (2008) Mitochondrial involvement in psychiatric disorders. Annals of Medicine, 40, 281-295.
[10]	Mann, V.M., Cooper, J.M., Krige, D., Daniel, S.E., Schapira, A.H.V. and Marsden, C.D. (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Рarkinson’s disease. Brain, 115, 333-342.
[11]	Dror, N., Klein, E., Karry, R., Sheinkman, A., Kirsh, Z., Mazor, M., Tzukerman, M. and Ben-Shachar D. (2002) State-dependent alterations in mitochondrial complex I activity in platelets: A potential peripheral marker for schizophrenia. Molecular Psychiatry, 7, 995-1001.
[12]	B?hm, M., Papezova, H., Hansikova, H., Wenchich, L. and Zeman, J. (2007) Activities of respiratory chain complexes in isolated platelets in females with anorexia nervosa. International Journal of Eating Disorders, 40, 659-663. doi:10.1002/eat.20403
[13]	Ben-Shachar, D. and Klein, E. (2008) Methods and kits for diagnosis of schizophrenia. US Patent, 7, 442-496.
[14]	Valla, J., Schneider, L., Niedzielko, T., Coon, K.D., Caselli, R., Sabbagh, M.N., Ahern, G.L., Baxter, L., Alexander, G., Walker, D.G. and Reiman, E.M. (2006) Impaired platelet mitochondrial activity in Alzheimer’s disease and mild cognitive impairment. Mitochondrion, 6, 323-330.
[15]	Burbaeva, G.Sh., Boksha, I.S., Turishcheva, M.S., Tereshkina, E.B., Savushkina, O.K., Starodubtseva, L.I., Fedorova, Ya.B. and Gavrilova, S.I. (2008) Cytochrome c- oxidase and glutamine synthetase-like protein in blood platelets as candidates for the role of early markers of Alzheimer’s disease. Proceedings of the IV-th Scientific and Practical Conference “Alzheimer’s disease and cognitive impairments in old age: Advances in neurobiology and therapy”, 89-97 [Russian].
[16]	Boksha, I., Burbaeva, G., Savushkina, O., Tereshkina, E., Turishcheva, M., Starodubtseva, L. and Vorobyeva, E. (2009) Blood proteins as markers and predictors of cognitive deficit in mental pathologies. Abstracts, 3rd World Congress Gene-2009, Foshan, China. http://www.bitlifesciences.com/wcg2009/Program.asp
[17]	Benecke, R., Strümper, P. and Weiss, H. (1993) Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116, 1451-1463. doi:10.1093/brain/116.6.1451
[18]	Parker, W.D. Jr and Parks, J.K. (1995) Cytochrome c- oxidase in Alzheimer’s disease brain: purification and characterization. Neurology, 45, 482-486.
[19]	Cardoso, S.M., Proenca, M.T., Santos, S., Santana, I. and Oliveira, C.R. (2004) Cytochrome c-oxidase is decreased in Alzheimer’s disease platelets. Neurobiology of Aging, 25, 105-110. doi:10.1016/S0197-4580(03)00033-2
[20]	Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with the folin phenol reagent. The Journal of Biological Chemistry, 193, 265- 275.
[21]	Kato, T. (2001) The other, forgotten genome: Mitochondrial DNA and mental disorders. Molecular Psychiatry, 6, 625-633. doi:10.1038/sj.mp.4000926
[22]	Washizuka, S., Iwamoto, K., Kakiuchi, C., Bundo, M. and Kato, T. (2009) Expression of mitochondrial complex I subunit gene NDUFV2 in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. Neuroscience Research, 63, 199-204. doi:10.1016/j.neures.2008.12.004
[23]	Maurer, I. and Moller, H.J. (1997) Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Molecular and Cellular Biochemistry, 174, 255-259. doi:10.1023/A:1006872911332
[24]	Streck, E.L., Rezin, G.T., Barbosa, L.M., Assis, L.C., Grandi, E. and Quevedo, J. (2007) Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain. Naunyn-Schmiedeberg’s Archives of Pharmacology, 376, 127-133. doi:10.1007/s00210-007-0178-2
[25]	Casademont, J., Garrabou, G., Miró, ò., López, S., Pons, A., Bernardo, M. and Cardellach, F. (2007) Neuroleptic treatment effect on mitochondrial electron transport chain: Peripheral blood mononuclear cells analysis in psychotic patients. Journal of Clinical Psychopharmacology, 27, 284-288. doi:10.1097/JCP.0b013e318054753e
[26]	Burbaeva, G.Sh., Boksha, I.S., Tereshkina, E.B., Savushkina, O.K., Turishcheva, M.S., Starodubtseva, L.I., Brusov, O.S. and Morozova, M.A. (2006) Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia. The World Journal of Biological Psychiatry, 7, 75-81. doi:10.1080/15622970510029957
[27]	Wechsler, D. (1981) Wechsler adult intelligence scale- revised,San Antonio, TX: Psychological Corporation.
[28]	Marder, S.R., Davis, J.M. and Chouinard, G. (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. The Journal of Clinical Psychiatry, 58, 538-546. doi:10.4088/JCP.v58n1205